Use of anti-D immunoglobulin in the treatment of threatened miscarriage in the accident and emergency department

L Weinberg

Abstract

Background—The UK guidelines for the use of anti-D immunoglobulin for rhesus prophylaxis have been revised. Anti-D immunoglobulin is no longer recommended for Rh D negative women after a threatened miscarriage less than 12 weeks gestation. These patients are at risk of rhesus immunisation, and there should be a policy for their treatment in the accident and emergency (A&E) department.

Design—A retrospective study over a 17 month period was conducted looking at women presented to an A&E department with a threatened miscarriage.

Objectives—To determine how many of these patients presented with heavy or repeated bleeding, or abdominal pain, and whether the guidelines for the use of rhesus prophylaxis were followed.

Results—112 women fulfilled the criteria for inclusion. Nineteen patients were Rh D negative. Eighty three patients (74.1%) presented with either abdominal pain or heavy or recurrent bleeding. Rhesus status was recorded in the A&E notes in only 15 patients (13.3%). Ninety seven patients (86.6%) were discharged without rhesus status being checked. Fifteen Rh D negative patients were discharged without being offered anti-D immunoglobulin.

Conclusion—Many women who present to the A&E department with a threatened miscarriage of less than 12 weeks gestation have heavy or recurrent bleeding or associated abdominal pain. These patients have an increased risk of fetomaternal haemorrhage and the consequent development of haemolytic disease of the newborn is possible. It should be mandatory for the A&E department to record rhesus status. In the context of A&E medicine, anti-D immunoglobulin should still be offered to all non-immune Rh D negative women presenting with a threatened miscarriage less than 12 weeks gestation.

Keywords: anti-D immunoglobulin; miscarriage; rhesus prophylaxis

The accident and emergency (A&E) department plays an important part in the treatment of women who present with a threatened miscarriage. Vaginal bleeding occurs in one fifth of recognised pregnancies before the 20th week, and of these over half end in a miscarriage. A&E departments provide a 24 hour service and are often the first port of call for many women who develop bleeding during pregnancy. It is essential that there is a policy for treating these patients especially Rh D negative women, who are at risk of rhesus immunisation resulting in haemolytic disease of the newborn (HDN). HDN is a haemolytic anaemia of fetal Rh positive red blood cells, characterised by varying degrees of anaemia, hyperbilirubinaemia, oedema, cardiac failure, heptosplenomegaly and life threatening neurological sequelae of encephalopathy and convulsions, which occurs when there is incompatibility between fetal and maternal blood groups.

Anti-D immunoglobulin has been used for rhesus prophylaxis in the United Kingdom since 1969, reducing the number of deaths attributed to rhesus alloimmunisation from 46/100 000 in 1969 to 1.6/100 000 in 1990. However, sensitisation still occurs in several patients, often resulting from failed or delayed administration of anti-D immunoglobulin after a potentially sensitising event.

When Rh D immunoprophylaxis was initially introduced in the UK only postnatal treatment was recommended. In 1976 the department of health further advocated the use of anti-D immunoglobulin to cover all abortions, irrespective of gestational age. This was the current management policy until March 1999, when a joint working group of the British Transfusion Society and the Royal College of Obstetricians and Gynaecologists revised the existing guidelines for the use of anti-D immunoglobulin for rhesus prophylaxis. The updated revised guidelines list all potential sensitising events for which anti-D immunoglobulin must be given (see box).

The updated 1999 guidelines differ from the previous guidelines in that anti-D immunoglobulin is now no longer recommended for Rh D negative women presenting with a threatened miscarriage with a viable fetus less than 12 weeks gestation. This is because most vaginal bleeding of less than 12 weeks gestation is mostly from maternal vessels in the decidua or cervix and not from fetal vessels in the chorionic villi, thereby minimising the risk of fetomaternal haemorrhage.

Fetomaternal haemorrhage is more common if the choriodecidual space is breeched, which occurs after therapeutic or complete miscarriage. Approximately 4% of women who have a therapeutic miscarriage will have a transplacent al haemorrhage of > 0.2 ml of fetal red
Anti-D immunoglobulin and the treatment of threatened miscarriage

100
120
20
60
80
0
Total patients
Patients presenting with associated abdominal pain or heavy bleeding
Patients with associated abdominal pain
Patients with associated heavy bleeding
Patients with bleeding > 72 h

Figure 1 Patients presenting with abdominal pain and vaginal bleeding.

Sensitising events during pregnancy for which anti-D immunoglobulin must be given to Rh D negative women.8
- Abortion
- Therapeutic termination of pregnancy—any gestation
- Ectopic pregnancy
- Spontaneous complete miscarriage > 12 weeks gestation
- Closed abdominal injury
- Antepartum haemorrhage
- Intrauterine death
- Stillbirth
- Invasive prenatal diagnostic procedures
- External cephalic version
- Delivery of an Rh D positive fetus
- Intrauterine procedures

cells, and of these patients 4%–5% will become sensitised. Choriodecidual space bleeding does occur after a threatened miscarriage, although the volume of fetal red cells is smaller (< 0.1 ml). However, it is has been shown in the literature that sensitisation can occur in up to 3% of women exposed to a transplacental haemorrhage of < 0.1 ml, therefore it can follow a threatened miscarriage of less than 12 weeks gestation. It seems feasible that such events are even more common when bleeding is heavy, painful or recurrent, although there is no evidence to support this.

The revised national guidelines, however state that it is “still prudent” to administer rhesus D prophylaxis when bleeding is heavy, repeated or if there is associated abdominal pain, particularly if these events occur near to 12 weeks gestation. If the gestation period is unknown, it should be confirmed by ultrasound. If bleeding continues intermittently after 12 weeks gestation, anti-D immunoglobulin should be given at six weekly intervals. The dose of anti-D immunoglobulin is 250 IU (50 µg), which should be administered by deep intramuscular injection, preferably into the deltoid muscle for optimal absorption, as soon as possible after the sensitising event, but always within 72 hours. If anti-D immunoglobulin is not given within the first 72 hours, a dose given within 9–10 days may provide some protection.

The objectives of this study were to determine how many patients presenting to an A&E department with a threatened miscarriage of less than 12 weeks gestation had heavy or repeated bleeding, or associated abdominal pain, whether the guidelines, at the time of this study, for the use of anti-D immunoglobulin were followed, and to ascertain if the revised change to the 1999 UK guidelines concerning Rh D prophylaxis now not being indicated for a threatened miscarriage of less than 12 weeks gestation is justified, in the treatment of such patients, in an A&E department context.

Methods
The author conducted a retrospective study looking at pregnant women with a threatened miscarriage less than 12 weeks gestation who attended the A&E department of the St James’s University Hospital, Leeds, between 1 January 1998 and 31 May 1999 (17 months). The A&E department assesses about 90 000 patients each year and covers a population of 370 000.

Threatened miscarriage was defined as a patient who presented with pregnancy associated vaginal bleeding, and a positive immunological pregnancy test (urine or serum B HCG).

Gestational age was confirmed by the patient’s antenatal records, which included the last normal menstrual period date, expected date of delivery or a dating ultrasound report. The gestational age in patients with no prior antenatal assessment, was calculated by the A&E doctor from the date of the patient’s last normal menstrual period.

Only patients assessed and discharged solely by an A&E doctor were included in the sample population. Patients referred to the on call gynaecologist by the A&E doctor for further assessment or management, and those patients admitted to the ward, were excluded.

Data collected included whether blood grouping for rhesus status was considered and recorded, whether anti-D immunoglobulin was administered to Rh D negative women, and what follow up was arranged for the patient once discharged from the A&E department.

Results
Because of the nature of the study, there is no statistical validation for any of the figures. Patients’ blood grouping results were obtained by the author at the end of the study period from the regional Blood Transfusion Service.

The results are summarised in figure 1 and figure 2. One hundred and twelve women fulfilled the criteria for inclusion of whom 19 were Rh D negative. Rhesus status was recorded in the A&E notes in only 15 patients (13.3%), six of whom were Rh D negative. Four of these Rh D negative patients were given anti-D immunoglobulin in the A&E department. One hundred patients (89.2%)
were referred to an early pregnancy unit for further assessment and management.

Discussion
The study highlights the large proportion of women who present to the A&E department with a threatened miscarriage of less than 12 weeks gestation, who have abdominal pain, or heavy or recurrent bleeding. It also emphasises the importance of checking and recording the patient’s rhesus status.

It is clear that the guidelines for rhesus prophylaxis were not being followed. These results are comparable to research done in other A&E departments. A prospective study including 109 A&E departments in England and Wales concluded that 77% of the departments did not administer anti-D when appropriate. Two other papers looking at the use of anti-D in the A&E department confirmed rhesus status was not being recorded in 72% and 86% of their patients, and none of the rhesus D negative patients discharged were offered anti-D immunoglobulin.

The crucial question that needs to be answered is why national guidelines are not being followed? The NHS Research and Development Directorate have already identified this dilemma, and there is no universal answer.

Many A&E departments have facilities to refer pregnant women with a threatened miscarriage to an early pregnancy unit, and perhaps A&E doctors rely on these services for further assessment and continuation of treatment. This often is not optimal treatment for these patients, especially if they are rhesus D negative. Patients are frequently referred to the early pregnancy unit the following working day, and the recommended 72 hour cut off time for optimal benefit of anti-D immunoglobulin may be missed, especially if the patient has been bleeding for 72 hours at initial presentation (21.4% of patients this study), or if they present on a Friday or bank holiday weekend, where they may only be seen by the assessment unit 24–72 hours later. A simple analogy would be someone with mild or atypical chest pain, being told to come back the following morning to the ECG clinic for an ECG to see if there are any ischaemic changes. This makes no sense, and the same principle applies to Rh D negative women, who present with a threatened miscarriage. Anti-D immunoglobulin needs to be given immediately if indicated, avoiding the risk of sensitisation. Some patients may also default early pregnancy unit follow up.

Something needs to be done to optimise treatment of these patients. It would be ideal if we all knew our blood group and rhesus status or carried the information with us, but this is not practical. It is therefore mandatory for the A&E department to check rhesus status at initial presentation, and if indicated, it should be the responsibility of the A&E doctor to offer anti-D immunoglobulin, minimising risk of rhesus sensitisation.

Human anti-D immunoglobulin is manufactured from high titre anti-D plasma, and has had an impeccable safety record for over 30 years. The manufacturing process is known to remove and/or inactivate HbsAg, HIV-1, HIV-2, and HCV. Side effects are minor, which may include pain at the site of the injection, rash and itching. There are medicolegal risks involved if sensitisation does occur without anti-D immunoglobulin being administered, and the consequences of sensitisation, which may include loss of pregnancy, loss of subsequent pregnancies and invasive procedures, outweigh the relatively insignificant risk involved of anti-D immunoglobulin being given, therefore even if there is uncertainty about gestational age, or the patient does not give a reliable menstrual history, anti-D immunoglobulin should still be prescribed.

Increased awareness for rhesus prophylaxis may be achieved by the introduction of a stamp or protocol form prompting the documentation of rhesus status, or by allowing nursing staff to check blood grouping and document the rhesus status result. This places additional pressure on an already overstretched nursing service, and the extent of this burden would need to be evaluated. New A&E doctors need to be made aware that guidelines for the use of anti-D immunoglobulin are available, and updated guidelines should be available in all departments.

The revised updated guidelines for the use of anti-D immunoglobulin for rhesus prophylaxis exclude a threatened miscarriage of less than 12 weeks gestation as being a potentially sensitising event for which anti-D immunoglobulin should be given. There have been no randomised trials or cost-benefit analyses of anti-D immunoglobulin in threatened miscarriage, therefore the updated guidelines are no more evidence based than the previous guidelines that advocated its use for all miscarriages, including a threatened miscarriage of less than 12 weeks gestation.

This study clearly shows the high percentage of women who present to an A&E department with a threatened miscarriage of less than 12 weeks gestation who have heavy or recurrent bleeding or associated abdominal pain, and that the guidelines, at the time of the study, for the use of anti-D immunoglobulin were not followed. These patients have an increased risk of fetomaternal haemorrhage and transplacental

![Figure 2. Rhesus D negative patients and administration of anti-D immunoglobulin.](source)
bleeding, and the consequent development of haemolytic disease of the newborn is possible.

It should therefore be mandatory for all A&E doctors to document these patients’ rhesus D status, and in the context of A&E medicine, rhesus prophylaxis should still be offered to all non-immune Rh D negative women who present with a threatened miscarriage, including those patients with a gestational age of less than 12 weeks.

I am grateful for the invaluable support and assistance of Dr Robin Illingworth, head of the A&E Department at St James’s University Hospital, Leeds, without whom this research would not have been possible, and to Dr Paul Gaffney, Research Registrar at St James’s University Hospital for his advice and guidance in initiating this research.

Contributors
Dr Laurence Weinberg, designed the study, participated in data collection and documentation, formulated the primary objectives, analysed and interpreted the data, and wrote the paper.

Funding: none.

Conflicts of interest: none.


